CYP3A4
5 articles
Computational & AIJournal of Chemical Theory and Computation
Pairing induced fit docking with free energy calculations and a shared binding mode makes flexible, promiscuous anti-target proteins tractable for structure-based design
- Anti-targets such as CYP3A4, CYP2D6, hERG and PXR have large, flexible pockets that bind many ligands, which has made structure-based design against them difficult.
- The workflow combines induced fit docking with free energy perturbation, and requires a consensus binding mode across a congeneric series so that receptor conformations are sampled efficiently.
- It was evaluated retrospectively on public datasets and applied prospectively in ongoing discovery programs, supporting its use for steering compounds away from these liabilities.
The consensus-binding-mode requirement is both the trick and the weak spot. Promiscuous pockets like CYP3A4 and hERG routinely let close analogs flip poses, so FEP will look reliable exactly where the assumption holds and quietly fail where it doesn't. Before trusting it on my series, I'd check whether the method flags pose switches, and whether it beats a simple matched-pair trend on the assay we already run.
Computational & AIJournal of Chemical Theory and Computation (ACS)
Induced-fit docking plus free energy perturbation brings structure-based design to promiscuous ADMET anti-targets
- Combines induced-fit docking with free energy perturbation to model flexible, promiscuous anti-target proteins: CYP3A4, CYP2D6, hERG and PXR.
- Imposing one shared binding pose across a congeneric series lets the workflow sample many receptor conformations efficiently.
- Evaluated retrospectively on public datasets and applied prospectively in ongoing drug discovery programs, supporting lead optimization away from off-target liabilities.
The consensus-pose assumption is both the trick and the risk: for hERG and CYP3A4, ligands in one series can flip modes, and a forced shared pose will quietly bias the ranking. I'd want to see a no-FEP baseline (ligand-based QSAR or simple docking) on the same sets, plus the cases where the pose failed. Prospective use is encouraging, but hit rate is unreported here.
PharmacologybioRxiv
Human macrophages carry active CYP3A4, and cocaine boosts its activity
- Monocyte-derived macrophages from many donors expressed CYP3A4 with measurable activity, but mRNA, protein and enzyme activity correlated poorly across donors.
- Cocaine raised catalytic activity in every donor, to a level comparable with rifampicin, though its effect on expression varied.
- In rhesus macaques, cocaine coincided with lower tissue antiretroviral levels and higher CYP3A4 and PXR expression.
Expression-function discordance is a useful warning that mRNA or protein levels alone can mislead in this tissue. If cocaine induces CYP3A4 in the very cells that harbor HIV, tissue-level antiretroviral exposure could fall below what plasma PK suggests, and that is a drug-drug interaction I'd want modeled. The macaque link is correlative so far, and I'd like to see tissue concentrations tied directly to the macrophage effect.
PharmacologybioRxiv
CYP2C9 drives Δ8-THC conversion to its psychoactive 11-hydroxy metabolite
- In human liver microsomes, Δ8-THC gave several monohydroxylated products, led by the psychoactive 11-hydroxy metabolite; CYP2C9 emerged as main producer.
- Ring hydroxylation came mainly from CYP3A, side-chain oxidation from CYP2D6, CYP1A2 and CYP3A4.
- CYP2C9 handled Δ8-THC less efficiently than Δ9-THC, though C11 hydroxylation matters more for Δ8; loss-of-function genotypes were predicted to sharply cut 11-hydroxy formation, moving clearance to CYP3A4/CYP2C19.
Microsomes can tell you which enzyme makes the psychoactive metabolite; they can't tell you how a person's exposure will split. They give no in vivo exposure to the 11-hydroxy species, and the genotype effect is a prediction, not an observation. Clinical PK in CYP2C9 poor metabolizers, plus 2C9 inhibitor interaction data, would have to come before anyone calls this a risk factor.
Computational & AIJournal of Chemical Theory and Computation
Using induced-fit docking plus FEP to design away from CYP, hERG and PXR
- Anti-targets such as CYP3A4, CYP2D6, hERG and PXR have large, flexible sites that make structure-based design difficult.
- The workflow pairs induced-fit docking with free energy perturbation, enforcing a consensus binding mode across a congeneric series to sample receptor conformations efficiently.
- It was tested on public retrospective datasets and applied prospectively in active drug discovery programs.
Most teams treat hERG and CYP as a post-hoc assay problem; getting usable FEP on these promiscuous pockets would move liability into the design cycle. The consensus-binding-mode restriction is the clever bit, but it also limits you to congeneric series. Prospective hit rates on novel scaffolds will show whether this holds beyond the series it was tuned on.